Who
Thomas McGauley
Interim CFO
Company insider
Files Form 4 as: Interim CFO, Tenax Therapeutics; Chief Financial Officer, Galectin Therapeutics.
In numbers
- Trades disclosed
- 8
- Buys
- 2
- Sells
- 0
- Bought
- $82K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 23 May 2012
- Last trade
- 30 Jan 2026
- Last filed
- 3 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jan 2026filed 3 Feb 2026 | TENX Tenax Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | TENX Tenax Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 17 Nov 2025filed 19 Nov 2025 | TENX Tenax TherapeuticsBiotechnology | SEC FORM 4 Bought | $15K2,000 at $7.34 | filing |
| 17 Nov 2025filed 19 Nov 2025 | TENX Tenax TherapeuticsBiotechnology | SEC FORM 4 Bought | $7,3501,000 at $7.35 | filing |
| 17 Nov 2025filed 19 Nov 2025 | TENX Tenax TherapeuticsBiotechnology | SEC FORM 4 Bought | $36K5,000 at $7.23 | filing |
| 19 Jun 2013filed 21 Jun 2013 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 24 May 2012filed 25 May 2012 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $24K10,000 at $2.35 | filing |
| 23 May 2012filed 25 May 2012 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.